Filter the drugs by the phase of research, how they help and the responsive mutations.
Cystic fibrosis is a genetic disease caused by mutations in the CFTR gene. Browse the
database of
drugs treating specific mutations compiled by the AIM tool.
| Drug | Marketed as | Description | Phase of research | How it helps |
|---|---|---|---|---|
| Eluforsen | 33-nucleotide antisense oligonucleotide designed to restore CFTR function |
Phase One Clinical Trial | Restore CFTR Function | |
| Endothelin 1 | CFTR corrector |
Pre-clinical | Restore CFTR Function | |
| Epoxomicin | Proteasome inhibitor preventing premature CFTR breakdown |
Pre-clinical | Restore CFTR Function | |
| G418 | Aminoglycoside antibiotic capable of translational readthrough |
Pre-clinical | Restore CFTR Function | |
| GLPG1837 | Small molecule CFTR potentiator |
Pre-clinical | Restore CFTR Function | |
| GLPG2222 | CFTR corrector |
Phase Two Clinical Trial | Restore CFTR Function | |
| GLPG2451 | Small molecule CFTR potentiator |
Pre-clinical | Restore CFTR Function | |
| GORASP1 | CFTR corrector |
Pre-clinical | Restore CFTR Function | |
| Galectin-3 | CFTR corrector |
Pre-clinical | Restore CFTR Function | |
| Gallium | Kills antibiotic-resistant strains of Pseudomonas aeruginosa |
Phase Two Clinical Trial | Anti-Infective |
